Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1989 Mar;52(3):324–328. doi: 10.1136/jnnp.52.3.324

The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years.

M A Hely 1, J G Morris 1, D Rail 1, W G Reid 1, D J O'Sullivan 1, P M Williamson 1, S Genge 1, G A Broe 1
PMCID: PMC1032404  PMID: 2647907

Abstract

One hundred and twenty nine de novo patients with idiopathic Parkinson's disease are being followed over a 5 year period in a double-blind multicentre study comparing low-dose bromocriptine (less than 30 mg/day) with low-dose levodopa-carbidopa (less than 600/150 mg/day). Sixty six patients have been randomised to bromocriptine and 63 patients to levodopa-carbidopa. Improvement has been greater in the levodopa-carbidopa group than in the bromocriptine group. Involuntary movements have so far only occurred in patients on levodopa-carbidopa, the incidence being much lower than is usually described with conventional doses. Mild, end-of-dose failure has occurred in both treatment groups; however, no patient has developed the "on-off" phenomenon. Low-dose levodopa-carbidopa appears to be a more effective anti-Parkinsonian treatment than low-dose bromocriptine but more prone to cause dyskinesia.

Full text

PDF
324

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbeau A. Six years of high-level levodopa therapy in severely akinetic parkinsonian patients. Arch Neurol. 1976 May;33(5):333–338. doi: 10.1001/archneur.1976.00500050019004. [DOI] [PubMed] [Google Scholar]
  2. Boshes B. Sinemet and the treatment of Parkinsonism. Ann Intern Med. 1981 Mar;94(3):364–370. doi: 10.7326/0003-4819-94-3-364. [DOI] [PubMed] [Google Scholar]
  3. CANTER G. J., DE LA TORRE R., MIER M. A method for evaluating disability in patients with Parkinson's disease. J Nerv Ment Dis. 1961 Aug;133:143–147. doi: 10.1097/00005053-196108000-00010. [DOI] [PubMed] [Google Scholar]
  4. Fahn S., Cote L. J., Snider S. R., Barrett R. E., Isgreen W. P. The role of bromocriptine in the treatment of parkinsonism. Neurology. 1979 Aug;29(8):1077–1083. doi: 10.1212/wnl.29.8.1077. [DOI] [PubMed] [Google Scholar]
  5. Grimes J. D., Delgado M. R. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease. Clin Neuropharmacol. 1985;8(1):73–77. [PubMed] [Google Scholar]
  6. Hoehn M. M. Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease. Acta Neurol Scand. 1985 Feb;71(2):97–106. doi: 10.1111/j.1600-0404.1985.tb03173.x. [DOI] [PubMed] [Google Scholar]
  7. Hofmann W. W., Angel R. W. Transient responses of the normal and diseased motor system to sudden load changes. Neurology. 1967 Oct;17(10):952–960. doi: 10.1212/wnl.17.10.952. [DOI] [PubMed] [Google Scholar]
  8. Lee J. E., Sweet R. D., McDowell F. H. Treatment of parkinsonism with levodopa. Follow-up after 2 years of treatment. Ann Intern Med. 1971 Nov;75(5):703–708. doi: 10.7326/0003-4819-75-5-703. [DOI] [PubMed] [Google Scholar]
  9. Lees A. J., Stern G. M. Sustained low-dose levodopa therapy in Parkinson's disease: a 3-year follow-up. Adv Neurol. 1983;37:9–15. [PubMed] [Google Scholar]
  10. Lees A. J., Stern G. M. Sustained low-dose levodopa therapy in Parkinson's disease: a 3-year follow-up. Adv Neurol. 1983;37:9–15. [PubMed] [Google Scholar]
  11. Marsden C. D., Parkes J. D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 1976 Feb 7;1(7954):292–296. doi: 10.1016/s0140-6736(76)91416-1. [DOI] [PubMed] [Google Scholar]
  12. Melamed E. Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease. Arch Neurol. 1979 May;36(5):308–310. doi: 10.1001/archneur.1979.00500410086014. [DOI] [PubMed] [Google Scholar]
  13. Muenter M. D., Sharpless N. S., Tyce G. M., Darley F. L. Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease. Mayo Clin Proc. 1977 Mar;52(3):163–174. [PubMed] [Google Scholar]
  14. Parkes J. D. Bromocriptine in the treatment of parkinsonism. Drugs. 1979 May;17(5):365–382. doi: 10.2165/00003495-197917050-00006. [DOI] [PubMed] [Google Scholar]
  15. Parkes J. D., Marsden C. D., Donaldson I., Galea-Debono A., Walters J., Kennedy G., Asselman P. Bromocriptine treatment in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1976 Feb;39(2):184–193. doi: 10.1136/jnnp.39.2.184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Pfeiffer R. F., Wilken K., Glaeske C., Lorenzo A. S. Low-dose bromocriptine therapy in Parkinson's disease. Arch Neurol. 1985 Jun;42(6):586–588. doi: 10.1001/archneur.1985.04060060092015. [DOI] [PubMed] [Google Scholar]
  17. Poewe W. H., Lees A. J., Stern G. M. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology. 1986 Nov;36(11):1528–1530. doi: 10.1212/wnl.36.11.1528. [DOI] [PubMed] [Google Scholar]
  18. Rajput A. H., Stern W., Laverty W. H. Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology. 1984 Aug;34(8):991–996. doi: 10.1212/wnl.34.8.991. [DOI] [PubMed] [Google Scholar]
  19. Rascol A., Montastruc J. L., Rascol O. Should dopamine agonists be given early or late in the treatment of Parkinson's disease? Can J Neurol Sci. 1984 Feb;11(1 Suppl):229–232. doi: 10.1017/s0317167100046461. [DOI] [PubMed] [Google Scholar]
  20. Shaw K. M., Lees A. J., Stern G. M. The impact of treatment with levodopa on Parkinson's disease. Q J Med. 1980;49(195):283–293. [PubMed] [Google Scholar]
  21. Staal-Schreinemachers A. L., Wesseling H., Kamphuis D. J., vd Burg W., Lakke J. P. Low-dose bromocriptine therapy in Parkinson's disease: double-blind, placebo-controlled study. Neurology. 1986 Feb;36(2):291–293. doi: 10.1212/wnl.36.2.291. [DOI] [PubMed] [Google Scholar]
  22. Stern G. M., Lees A. J. Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson's disease. Adv Neurol. 1983;37:17–21. [PubMed] [Google Scholar]
  23. Teychenne P. F., Bergsrud D., Racy A., Elton R. L., Vern B. Bromocriptine: low-dose therapy in Parkinson disease. Neurology. 1982 Jun;32(6):577–583. doi: 10.1212/wnl.32.6.577. [DOI] [PubMed] [Google Scholar]
  24. Yahr M. D. Limitations of long term use of antiparkinson drugs. Can J Neurol Sci. 1984 Feb;11(1 Suppl):191–194. doi: 10.1017/s0317167100046394. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES